Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +49.56%
#3 DOVU DOVU +49.39%
#4 Velvet Velvet +44.04%
#5 Black Phoenix Black Phoenix +34.54%
#6 τemplar τemplar +23.14%
#7 Cross Cross +18.32%
#8 Ribbita by Virtuals Ribbita by Virtuals +17.09%
#9 Cap Cap +16.96%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.04%
Coin of the day
Glidr Glidr
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Clasificación en acciones #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Precio por acción
$0.02468497
Capitalización bursátil
$1.01M
Cambio (1 día)
-12.50%
Cambio (1 año)
-87.34%
País
AU
Comercio Chimeric Therapeutics Limited (CHM)

Categoría

Healthcare
EPS de Chimeric Therapeutics Limited (CHM)
EPS a fecha de 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Chimeric Therapeutics Limited, el EPS actual de la empresa (TTM) es 0. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de Chimeric Therapeutics Limited desde 2026 hasta 2026
EPS al final de cada año
Año EPS Cambiar
Not enough data for the provided dates.
EPS de empresas similares o competidoras
Empresa EPS Diferencia de EPS País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE